Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze
Eli Lilly shares dipped slightly in premarket trading Wednesday, following a steep decline the day before that thrust the drugmaker back into focus in the obesity-drug sector. The stock was down roughly 0.5% at $998.50, after closing Tuesday at $1,003.21, slipping nearly 4%.